NEW YORK (TheStreet) -- RATINGS CHANGES
AmerisourceBergen (ABC) was upgraded at FBR Capital Markets to outperform. Twelve-month price target is $75. Stock has pulled back 10% over the past three months, FBR Capital Markets said.
Alkermes (ALKS) was upgraded at Mizuho to buy from neutral. Twelve-month price target is $61. Stock is attractive, following recent weakness, Mizuho said.
Must Read: Analysts' Actions: CVX DHR FBHS IP XOM
Cabot (COG) was downgraded at Stifel Nicolaus to hold from buy. Company will likely miss 2014 cash flow expectations, Stifel Nicolaus said. See fair value between $36 and $38, Stifel Nicolaus said.
CF Capital (CF) was downgraded at Barclays to equal-weight from overweight. Valuation call with near-term upside limited, Barclays said. Twelve-month price target is $267.
Dexcom (DXCM) was upgraded at Sterne Agee to buy from neutral. Twelve-month price target is $50. Superior CGM technology will continue to drive strong revenue growth, Sterne Agee said.
El Paso Pipeline Partners (EPB) initiated at UBS with a neutral rating. Recontracting will create some headwinds for the partnership, UBS said. Twelve-month price target is $32.
IBM (IBM) was initiated with a hold rating at Deutsche Bank. Twelve-month price target is $200. Virtualization continues to change the spending landscape, Deutsche Bank said.
Imperva (IMPV) was downgraded at Oppenheimer to perform from outperform. Twelve-month price target is $65. Company is seeing increased competition and weakness in the U.S., Oppenheimer said.
Mistras (MG) was downgraded to hold at TheStreet Ratings.